Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
British Journal of Haematology|September 6, 2003
Stromal-derived factor 1 and matrix metalloproteinase 9 levels in bone marrow and peripheral blood of patients mobilized by granulocyte colony-stimulating factor and chemotherapy. Relationship with mobilizing capacity of haematopoietic progenitor cellsAlexandra Carion, Lotfi Benboubker, Olivier Hérault, et al.
Haematologica|May 30, 2013
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaMeletios A Dimopoulos, Meral Beksac, Lotfi Benboubker, et al.
World Neurosurgery|June 9, 2023
Multiple Myeloma Spinal Lesion Care: Management of a Primary Bone Malignancy Rather Than a Spinal MetastasisAymeric Amelot, Louis-Marie Terrier, Louis-Romée Le Nail, et al.
Leukemia & Lymphoma|January 14, 2016
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myelomaPhilippe Moreau, Thierry Facon, Cyrille Touzeau, et al.
Blood|August 21, 2010
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation studyPhilippe Moreau, Arnaud Jaccard, Lotfi Benboubker, et al.
Experimental Hematology|January 25, 2003
Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrowLotfi Benboubker, Guillaume Cartron, Françoise Roingeard, et al.
Haematologica|September 28, 2014
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myelomaMeletios A Dimopoulos, Robert Z Orlowski, Thierry Facon, et al.
Leukemia Research|April 11, 2021
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysisSara Bringhen, Ludek Pour, Vladimir Vorobyev, et al.
Annals of Hematology|August 29, 2019
Characteristics, combinations, treatments, and survival of second primary hematological neoplasm: a retrospective single-center cohort of 49 patients (Hemo<sup>2</sup>study)Thomas Chalopin, Nicolas Vallet, Flavie Arbion, et al.
Blood|March 19, 2015
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myelomaPhilippe Moreau, Brigitte Kolb, Michel Attal, et al.
Pageof 7